A vaccine designed to block fentanyl from reaching the brain has entered Phase I human trials in the Netherlands after animal studies showed it could reduce opioid levels in the brain by roughly 70 percent, according to researchers at Scripps Research who published the findings in the Journal of Medicinal Chemistry in May.

The vaccine works differently from traditional immunizations. Rather than training the immune system to fight a pathogen, it prompts the body to produce antibodies that bind to fentanyl molecules in the bloodstream before they cross into the brain. The result, in mice given doses that would normally cause severe respiratory depression, was near-normal breathing. Animals that did not receive the vaccine showed the expected signs of overdose at the same dose.

The Phase I trial began in January 2026 and is enrolling 40 participants at a research center in the Netherlands. The trial’s primary goal is safety assessment, tracking whether the antibody response causes any adverse effects in humans. Efficacy data will come from later-stage trials if Phase I results are positive.

What separates this vaccine from earlier attempts to target fentanyl is its breadth. The Scripps Research team, led by chemist Kim Janda, designed the antibodies to recognize not only fentanyl itself but a range of structurally related designer drugs that have proliferated on the illicit market. Many fentanyl analogues are synthesized specifically to evade detection or increase potency, and previous vaccine candidates failed to keep pace with those chemical modifications.

The new platform attaches a fentanyl-like molecule to a carrier protein, triggering an immune response calibrated to the core chemical structure shared by most fentanyl variants. The team says the design makes it adaptive to future analogues without requiring the vaccine itself to be reformulated.

Fentanyl has been the primary driver of overdose deaths in the United States for a decade. The Centers for Disease Control and Prevention reported more than 70,000 opioid-related deaths in 2025, the majority involving illicit fentanyl or its analogues. Existing treatment options including naloxone can reverse an active overdose but require administration at the right moment. A preventive vaccine could offer protection that persists over months rather than minutes.

Researchers say the vaccine is most likely to be used in high-risk populations: people in recovery programs, individuals with prior overdose history, or first responders with occupational exposure. It would not replace naloxone or addiction treatment, but could serve as an additional layer of protection for those most vulnerable to accidental exposure. More science and health news, including breakthroughs in cancer treatment, can be found in our science section.

The full trial results from Phase I are expected by early 2027. If the safety profile is acceptable, Scripps Research and its commercial partners plan to move quickly into Phase II efficacy trials in the United States.

The research was funded in part through a grant from the National Institute on Drug Abuse, which has prioritized vaccine-based approaches to opioid prevention as part of a broader push to find solutions that operate upstream of an overdose event. Details on the trial are available through the official registry at ClinicalTrials.gov.